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Abstract
Anaemia is a chief determinant of globalill health, contributing to cognitive impairment, growth
retardation and impaired physical capacity. To understand further the genetic factors influencing
red blood cells, we carried out a genome-wide association study of haemoglobin concentration and
related parameters in up to 135,367 individuals. Here we identify 75 independent genetic loci
associated with one or more red blood cell phenotypes at P <10−8, which together explain 4–9% of
the phenotypic variance per trait. Using expression quantitative trait loci and bioinformatic
strategies, we identify 121 candidate genes enriched in functions relevant to red blood cell
biology. The candidate genes are expressed preferentially in red blood cell precursors, and 43 have
haematopoietic phenotypes in Mus musculus or Drosophila melanogaster. Through open-
chromatin and coding-variant analyses we identify potential causal genetic variants at 41 loci. Our
findings provide extensive new insights into genetic mechanisms and biological pathways
controlling red blood cell formation and function.
Haemoglobin, an iron-containing metalloprotein found in the red blood cells of all
vertebrates, provides the primary mechanism for oxygen transport in the circulation.
Haemoglobin levels and related red blood cell phenotypes are tightly regulated, including an
important genetic component1–5. To refine our understanding of the genetic factors
influencing red blood cell formation and function, we carried out a meta-analysis of
genome-wide association studies (GWAS) and staged follow-up genotyping of six red blood
cell phenotypes: haemoglobin, mean cell haemoglobin (MCH), mean cell haemoglobin
concentration (MCHC), mean cell volume (MCV), packed cell volume (PCV) and red blood
cell count (RBC).
Our study design is summarized in Supplementary Fig. 1. In brief, we combined genome-
wide association data from 71,861 individuals of European or South Asian ancestry, with up
to 2,644,161 autosomal single-nucleotide polymorphisms (SNPs) and 67,645 X-
chromosome SNPs. Characteristics of participants, genotyping arrays and imputation are
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summarized in Supplementary Tables 1–3. Meta-analysis was carried out among Europeans
and South Asians separately, followed by a final combined analysis of results from the two
populations. We performed replication testing of 22 loci showing suggestive association
(10−8<P <10−7) in a further 63,506 individuals using a combination of in silico data and
direct genotyping (Supplementary Tables 1, 2 and Supplementary Note). Genome-wide
significance was set at P <1 × 10−8, allowing a Bonferroni correction both for the ~106
independent SNPs tested6, as well as for the six inter-related red blood cell phenotypes
(Supplementary Note)7.
Seventy-five independent genetic loci reached genome-wide significance for association
with one or more red blood cell phenotypes (Table 1 and Supplementary Fig. 2), 43 of
which are novel. For descriptive and downstream purposes, we identified a single ‘sentinel’
SNP for each of the 75 loci, defined as the SNP with the lowest P value against any
phenotype at each locus; regional plots for the 75 loci are shown in Supplementary Fig. 3.
Full lists of the SNPs associated with phenotype at P <10−6 and of the sentinel SNPs are
provided (Supplementary Tables 4 and 5). Of the 38 loci previously reported to be
associated with red blood cell traits1–5, we replicate 32 loci (P <10−8) and find three to be
nominally associated (P <0.05; Supplementary Table 6). The remaining three loci, initially
reported in an East Asian GWAS4, were not associated with red blood cell phenotypes in
our sample (Supplementary Fig. 4 and Supplementary Note).
Among the 75 genomic loci identified, we found that 31 were associated with one red blood
cell phenotype, and 44 with two or more phenotypes, at P <10−8. The total number of locus–
phenotype associations identified at P <10−8 was 156, of which 92 are novel (Supplementary
Fig. 5 and Supplementary Table 7). In addition, at 8 of the 75 loci we found evidence for
multiple SNPs independently associated with red blood cell phenotype at P <10−8 in
conditional analyses8, suggesting the presence of possible secondary genetic mechanisms at
these loci (Supplementary Table 8).
Identification of candidate genes
There are >3,000 protein-coding genes within 1 megabase (Mb) of the sentinel SNPs from
the 75 genetic loci associated with red blood cell phenotypes. We prioritized genes as
probable candidates underlying the observed genetic associations using the following
criteria: (1) gene nearest to the sentinel SNP, and any other gene within 10 kilo-bases (kb)
(97 genes; Table 1); (2) gene containing a non-synonymous SNP in high linkage
disequilibrium (r2 >0.8) with the sentinel SNP (24 genes; Supplementary Table 9); (3) gene
with expression quantitative trait loci (eQTL) associated with sentinel SNP in peripheral
blood lymphocytes (27 genes; Supplementary Table 10); and (4) gene relationships among
implicated loci (GRAIL) literature analysis9 (9 genes; Supplementary Table 11). This
strategy identified 121 candidate genes (Table 1 and Supplementary Fig. 6).
Pathway analysis revealed that the list of candidate genes is strongly enriched for genes
known to be involved in haematological development and function (P = 10−63), as well as in
cellular proliferation, development and death, and immunological processes (Supplementary
Tables 12 and 13). Current knowledge of gene function for all 121 candidates is summarized
in Supplementary Table 14. Of note, some of the genes within these regions are known to
underlie the Mendelian red blood cell disorders of elliptocytosis, ovalocytosis and
spherocytosis (ANK1, SLC4A1, SPTA1)10, haemolytic anaemia (HK1)11 and iron
deficiency or overload (TMPRSS6, HFE, TFR2)12. Furthermore, somatic mutations of
IKZF1, KIT, SH2B3, SH3GL1 and TAL1 (also known as SCL) underlie several
haematologic proliferative disorders (Supplementary Table 14).
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Gene expression during haematopoiesis
We next explored expression of the 121 candidate genes using an atlas of 38 different
haematopoietic cell types (Supplementary Table 15)13. Ninety-seven genes could be reliably
assigned a probe on the Affymetrix HG_U133AAofAv2 array (Fig. 1a); these transcripts
were, on average, expressed at higher levels in late erythroblasts (or the precursors of red
blood cells, EB3–EB5) compared to other transcripts in the same cell type (P <0.01 after
Bonferroni correction; Fig. 1b). Furthermore, expression was more likely to be upregulated
in EB3–5 relative to other cell types (P = 1.2 × 10−6, rank-sum test).
To further investigate lineage-specific effects, we assessed temporal patterns of gene
expression during in vitro differentiation of haematopoietic stem cells to erythroblasts14. On
average, candidate genes have increasing expression over time along the erythroid lineage (P
=0.006, rank-sum test; Fig. 1c). These data support the view that the gene set identified here
is enriched for genes relevant to red blood cell biology, including a number of candidate
genes differentially regulated to increase their expression in late erythropoiesis.
Coding and regulatory sequence variants
To better capture common sequence variation at the 75 loci, we searched the 1000 Genomes
Project data set (www.1000genomes.org) and identified 39 non-synonymous SNPs that are
in high linkage disequilibrium (r2 >0.8) with sentinel SNPs at the red blood cell loci
(Supplementary Table 9). This represents a ~sixfold enrichment compared to the expectation
under the null hypothesis (P =0.01; Supplementary Note). Although re-sequencing will be
needed to obtain a complete assessment of variants at these loci, these non-synonymous sites
represent an initial set of candidates for genetic variants underlying the observed
associations with red blood cell phenotypes, potentially mediated through changes in protein
function.
We next searched for sequence variants at the red blood cell loci that might influence gene
regulation. We used formaldehyde-assisted isolation of regulatory elements followed by
next-generation sequencing (FAIRE-seq) to identify nucleosome-depleted regions (NDRs)
that may represent active regulatory elements15. We studied three haematologic cell types,
and found 103,308 unique NDRs, of which 38,014 were present in erythroblasts, 50,372 in
megakaryocytes and 34,833 in monocytes. We then searched the 1000 Genomes Project data
set and found 60 SNPs located within one of these NDRs that are either: (1) one of the 75
sentinel SNPs from the red blood cell GWAS, or (2) in high linkage disequilibrium (r2>0.8)
and located within 1 Mb of a sentinel SNP (Supplementary Table 16). The NDRs
overlapping these 60 SNPs were more likely to be erythroblast specific than expected by
chance (1.8-fold enrichment compared to background distribution of NDRs; P =0.007,
Bonferroni-adjusted binomial test); by contrast, there were fewer megakaryocyte-specific
NDRs coinciding with red blood cell SNPs (0.4-fold enrichment; P =0.007; Fig. 1d). This
pattern of erythroblast enrichment and megakaryocyte depletion was robust to the stringency
of NDR peak-calling (Supplementary Table 17). Our results indicate that regulatory
variation within the erythroid lineage may underlie the associations observed at several of
the loci identified in our red blood cell GWAS. The 19 genes closest to the 25 erythroblast-
specific NDRs were more likely to be upregulated during erythropoiesis compared to all
other expressed transcripts (P=6.3×10−6, rank-sum test; Supplementary Table 18), lending
further support to the view that the NDRs identified have a role in the regulation of genes
involved in erythropoiesis16,17. Interestingly, the SNPs associated with MCH at 16p11
overlap an erythroblast-specific NDR that coincides with the NPRL3 regulatory element in
the locus control region of the downstream haemoglobin-α locus18,19.
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Together our coding- and regulatory-variant analyses thus identify a set of ~100 SNPs
across 41 regions that are candidates for functional genomic elements influencing red blood
cell formation and function, and which constitutes a priority set for future experimental
evaluation.
Insights from mouse models
A systematic search of the Mouse Genome Informatics database reveals haematologic
phenotypes for 29 of the 100 candidate genes that have mouse homologues (Supplementary
Fig. 6 and Supplementary Tables 14, 19), including genes involved in cell cycle regulation:
CCNA2 (4q27), CCND2 (12p13) and CCND3 (6p21); genes coding for transcription factors
and their interacting proteins: BCL11A (2p16), CITED2 (6q24), IKZF1 (7p13) and TAL1
(1p32); and genes involved in growth factor or cytokine signalling: KIT (4q11), KITLG
(12q22), SH2B3 (12q24) and PTPRCAP (11q13). Among the gene products encoded at the
newly identified loci, KITLG, also known as stem cell factor, is the cognate ligand for the
KIT tyrosine kinase receptor20. KIT signalling is involved in the perinatal transition from
fetal to adult haemoglobin, in addition to maintenance, proliferation and differentiation of
haematopoietic stem cells21. Kitlg−/− and Kit−/− mice have low red blood cell
concentrations, anaemia and other haematological abnormalities. CCNA2, CCND2 and
CCND3 are cyclin-dependent kinases that contribute to initiation and progression of cell
division22. Knock-out models of these genes have a number of haematological
abnormalities, including reduced stem cell and red blood cell concentrations, and anaemia22.
Of the 29 candidate genes with a blood phenotype in mouse, 25 were identified as the genes
nearest to the sentinel SNP, and 15 through the eQTL (n =2), coding-variant (n = 6) or
GRAIL (n = 8) analyses (Supplementary Table 19).
RNAi silencing in D. melanogaster
We used haemocyte-specific RNA interference (RNAi) silencing in D. melanogaster to
further evaluate the candidate genes for their role in blood cell formation. We first carried
out permutation testing in a genome-wide D. melanogaster RNAi silencer screen
(Supplementary Note). Results confirmed that the 121 candidates are enriched for genes
with a blood cell phenotype in D. melanogaster, supporting the view that our GWAS
identifies a set of genes conserved across phyla and involved in blood cell formation or
survival.
We next created haemocyte-specific RNAi knockdowns for 96 D. melanogaster genes that
are orthologues for 74 of the 121 candidate genes, and assessed blood cell formation (crystal
cells and plasmatocytes) in early- and late-stage L3 larvae23. We found 19 out of the 74
candidate genes with orthologues in D. melanogaster to have a blood cell phenotype, of
which 5 also have a haematological phenotypes in mouse models: KIT, HK1, CCNA2,
AP3D1 and PSMB10 (Supplementary Tables 19 and 20). Among the genes highlighted,
RNAi silencing of KIT and CCNA2 orthologues was associated with a profound reduction
in plasmocyte formation (Fig. 2), consistent with their established role in cytokinesis20,22.
AP3D1 is involved in vesicular trafficking and dense granule formation in platelets24,
whereas PSMB10 is a component of a widely distributed proteasome linked to inflammation
and ubiquitin signalling25. UBE2L3 is also involved in ubiquitin signalling and immune
regulation26, and genetic variants in UBE2L3 are strongly associated with several
autoimmune diseases known to influence blood cell counts27,28. EIF5 (14q32) is involved in
activation of the ribosomal initiation complex29, whereas RPS6KB2 (22q11) is a key
component of growth factor and other signalling cascades that regulate ribosomal function,
cellular proliferation and survival30. For most of the genes identified, the mechanisms
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underlying their potential relationship to red cell biology remain to be elucidated; our gene
set thus provides a rich resource for future experimental evaluation and discovery.
Contribution to clinical phenotype
The 75 sentinel SNPs together account for between 3.9% (PCV) and 8.9% (MCV) of
population variation in red blood cell phenotypes (Supplementary Table 21). Individuals in
the highest quartile of genetic risk score (GRS; on the basis of weighted effect of the 75
sentinel SNPs) are 3–5-fold more likely to be in the highest quartile for population
distribution of MCH, MCV and RBC (Fig. 3). GRS is associated with haemoglobin
concentrations across the physiological range, including at haemoglobin levels that predict
adverse outcomes in pregnancy, cardiovascular and neurologic disease, in addition to
mortality in the elderly31–34.
We next investigated the association of the 75 sentinel SNPs with red blood cell phenotypes
in thalassaemia, a group of genetic disorders characterized by defects in haemoglobin
synthesis and anaemia. We confirmed association of several of the sentinel SNPs with
respective blood cell trait, and found that GRS predicts phenotype similarly, among 460 β-
thalassaemia heterozygotes (Supplementary Table 22 and Supplementary Note). In separate
experiments, GRS predicts time to first blood transfusion among 495 patients with
thalassaemia major (P =6.9 × 10−4); however, this effect was fully accounted for by the
MYB-HBS1L locus, which modifies the severity of thalassaemia major through its effect on
fetal haemoglobin levels (Supplementary Note)35. Together, our findings demonstrate that
the common genetic variants identified contribute to phenotypic variation in the general
population, and suggest that they may also act as genetic modifiers in clinically relevant red
blood cell abnormalities.
Conclusions
Our genome-wide association and replication study in 135,367 individuals identifies 75
genetic loci influencing red blood cell phenotypes, and 156 locus–phenotype associations;
most of these discoveries are novel. Through open-chromatin and coding-variant studies, we
identify a first set of SNPs as potential causal variants. In parallel, our bioinformatic
strategies identify a core set of genes, differentially regulated in haematologic precursor
cells, which are candidates for mediating the effects on red blood cell phenotypes. However,
despite our extensive GWAS, bioinformatic and experimental data, the precise identities of
the causal variants, regulatory regions and genes remain to be determined; definitive
identification will require further detailed experimental evaluation. Our results thus provide
new insights into the genes and gene variants that may influence haemoglobin levels and
related red blood cell indices, and will underpin a deeper knowledge of the biological
mechanisms involved in haematopoiesis and red blood cell function.
METHODS
Genome-wide association
Genome-wide association was carried out in 62,553 people of European ancestry and 9,308
people of South Asian ancestry, using up to 2,644,161 autosomal and 67,645 X-
chromosome SNPs. Imputation was done using haplotypes from HapMap Phase 2.
Characteristics of participants, genotyping arrays and imputation are summarized in
Supplementary Tables 1 and 2. Participants with extreme measurements (> ± 3 s.d. from
mean) were excluded on a per-phenotype basis. Each population cohort was approved by a
research ethics committee, and all participants gave informed consent.
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SNP associations with each phenotype were tested by linear regression using an additive
genetic model. Associations were tested separately in men and women in each cohort, with
principal components and other study-specific factors as covariates to account of population
substructure as described in Supplementary Table 2. Test statistics from each cohort were
then corrected for their respective genomic-control inflation factor to adjust for residual
population sub-structure; genomic-control inflation factors are summarized in
Supplementary Table 3. We then carried out a meta-analysis of results from the individual
cohorts using Z-scores weighted by the square root of sample size. The meta-analysis was
varied out among Europeans and South Asians separately. There were no South-Asian-
specific discoveries, but also little evidence for heterogeneity of effect at known or new
genetic loci (Supplementary Table 23); we therefore carried out a final combined analysis of
results for the two populations. SNPs with minor allele frequency <1% (weighted average
across cohorts) were removed, as were SNPs with weight <50% of phenotype sample size.
There was no evidence for inflation of test statistics at SNPs not known to be associated
with red blood cell phenotypes (Supplementary Table 3), and genomic control was not
applied to the final meta-analysis results. We used the function ‘clump’ implemented in
PLINK to cluster the SNPs into genomic loci using a 2-Mb window; clustering was done
separately for each phenotype. Inverse variance meta-analysis was used to quantify effect
sizes for SNPs of interest.
Genome-wide significance was inferred at P <1 × 10−8. This choice of statistical threshold
was grounded on the guidelines derived from studies of the ENCODE (encyclopedia of
DNA elements) regions6, combined with results of permutation testing to determine the
additional adjustment needed for the six red blood cell phenotypes studied (Supplementary
Tables 24, 25 and Supplementary Note). As an alternative strategy, a P-value threshold of P
<3.2 × 10−9 would provide correction for the number of SNP–phenotype combinations
tested without any adjustment for the correlations between the SNPs or phenotypes tested.
We note that 70 of the 75 loci identified would exceed such a highly stringent threshold,
including all four of the loci identified through the joint analysis of European and South
Asian data.
Replication testing
We carried out replication testing of 22 SNPs selected on the basis of the following criteria:
(1) the lead SNP from each of 17 loci showing suggestive evidence for association with one
or more red blood cell phenotypes in Europeans (P >10−8 and P <10−7), and (2) the lead
SNP from each of the loci identified through combined analysis of genome-wide association
data for Europeans and South Asians. Replication testing was done using a combination of
in silico results and direct genotyping among 63,506 people from four population cohorts.
In silico data were available for 34,843 people from Iceland participating in the deCODE
(diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe) study37
(Supplementary Table 1). SNPs were directly genotyped with the Illumina HumanHap300
or CNV370 chips or imputed from one or more of four sources: the HapMap2 CEU sample
(60 triads), the 1000 Genomes Project data (179 individuals) and Icelandic samples
genotyped with the Illumina Human1 M-Duo (123 triads) or the HumanOmni1-Quad chips
(505 individuals), as previously described in ref. 37. The 22 SNPs were tested for
association against their respective discovery phenotypes, under an additive genetic model;
results were combined with the genome-wide association data by weighted-Z-score meta-
analysis.
We found that for 7 of the 22 SNPs carried forward for replication, their associations with
phenotype remained inconclusive after in silico testing (P >10−8 but P <10−7). For these
SNPs we carried out additional direct genotyping using Sequenom assays, among up to
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20,066 people from three population cohorts (Supplementary Table 1). Associations were
tested in each cohort separately, and results combined across the replication cohorts, and
then with the genome-wide association data, by weighted-Z-score meta-analysis
(Supplementary Table 26).
Conditional analysis
We performed conditional-association analysis using the summary statistics from the meta-
analysis to test for the association of each SNP while conditioning on the top SNPs, with
correlations between SNPs due to linkage disequilibrium estimated from the imputed
genotype data from the atherosclerosis risk in communities (ARIC) cohort8,38. Secondary-
association signals were selected with conditional-association P <1 × 10−8.
Identification of candidate genes
We considered the nearest gene, and any other gene located within 10 kb of the sentinel
SNP, to be a candidate for mediating the association with red blood cell phenotype. We also
used coding variant, eQTL and literature analyses to identify candidate genes. On the basis
of analysis of linkage-disequilibrium relations at the 75 genetic loci, we defined genomic
region as the 1-Mb interval either side of the sentinel SNP for our functional genomic
studies (Supplementary Fig. 7).
Coding variation
We identified all non-synonymous SNPs that were in linkage disequilibrium with one or
more of the sentinel SNPs at r2 >0.8 in 1000 Genomes Project data set (released in March
2012). We considered the gene to be a candidate when the non-synonymous and sentinel
SNPs were in linkage disequilibrium at r2 >0.8 and with no evidence for heterogeneity of
effect on phenotype. This strategy identified 39 non-synonymous SNPs distributed between
24 genes (Supplementary Table 9), representing a ~sixfold enrichment compared to the
mean number expected under the null hypothesis generated by permutation testing of SNP
sets matched for allele frequency (±0.05) and number of genes in proximity (±10 kb), but
selected otherwise at random (P =0.01; Supplementary Note).
Expression analyses
To identify the possible genes influencing red blood cell phenotypes at the 75 loci, we
examined the association of the sentinel SNPs with eQTL data from two data sets: (1)
peripheral blood lymphocytes from 206 families of European descent (830 parents and
offspring)39 and (2) peripheral blood lymphocytes from 1,469 unrelated individuals40.
SNPs were tested for association with expression of nearby (1 Mb) genes (P <0.05 after
Bonferroni correction for number of SNP–transcript associations tested). Where eQTLs
were identified, we used the whole-genome SNP data available in these data sets (imputed
with HapMap Phase 2 genotypes), to identify the SNP at the locus most closely associated
with transcript level (the transcript SNP). We then tested whether the sentinel SNP and the
transcript SNP were coincident, defined as r2 >0.8 with no evidence for heterogeneity of
effect on phenotype or transcript level (P >0.05). This strategy identified eQTLs involving
28 genes from 18 loci (Supplementary Table 10).
GRAIL analyses
We carried out a literature analysis using the GRAIL algorithm9, a statistical tool that uses
text mining of PubMed abstracts to annotate candidate genes from loci associated with
phenotypic traits. We carried out the analysis using the 2006 data set to avoid confounding
by subsequent GWAS discoveries; results identified candidate genes at nine loci (P <0.05;
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Supplementary Table 11). Results are also shown for a GRAIL analysis using the 2011
PubMed data set, although these were not used for the final analysis.
Gene expression in haematopoietic precursors
Cord-blood-derived CD34+ haematopoietic stem cells were differentiated in vitro along the
erythroid lineage in the presence of 6 U ml−1 erythropoietin (R&D Systems), 10 ng ml−1
inter-leukin (IL)-3 (Miltenyi Biotec) and 100 ng ml−1 stem cell factor (R&D Systems). Cells
were collected at days 3, 5, 7, 9 and 10 in three biological replicates and gene expression
was assayed using Illumina human WGv3.0 microarrays41. For each gene, we determined
the relationship of gene expression with time using linear regression, and calculated the t-
statistic for the difference in β from zero. We then classified gene-expression patterns as
increasing, decreasing or unchanged on the basis of the 2.5% and 97.5% quartiles of the t
distribution with 4 degrees of freedom. To test whether a gene set was enriched for
differentially regulated genes, a Wilcoxon signed-rank test of the t scores in the gene set
relative to all others genes that were expressed in at least one time point was calculated.
FAIRE-seq
We generated maps of chromatin accessibility (‘open chromatin’) in primary human
erythroblasts and megakaryocytes, and in peripheral blood monocytes using FAIRE-seq.
Cord-blood-derived CD34+ haematopoietic progenitor cells from two unrelated individuals
were differentiated in vitro into either erythroblasts (in the presence of erythropoietin, IL-3
and stem cell factor) or megakaryocytes (in the presence of thrombopoietin and IL-1β).
Monocytes were purified from leukocyte cones of apheresis collections from another two
individuals.
FAIRE experiments were performed as previously described in ref. 42. FAIRE DNA was
processed following the Illumina paired-end library-generation protocol. Genomic libraries
derived from erythroblast and megakaryocyte cultures were sequenced with 54-bp paired-
end reads on Illumina Genome Analyzer II. Libraries derived from monocyte extractions
were sequenced with 50-bp paired-end reads on Illumina HiSeq. Raw sequence reads were
aligned to the human reference sequence (NCBI build 37) using the read mapper Stampy43.
Reads were realigned around known insertions and deletions, followed by base-quality
recalibration using the Genome Analysis Toolkit (GATK)44. Duplicates were flagged using
the software Picard (http://picard.sourceforge.net/) and excluded from subsequent analyses.
For each cell type, we merged all read fragments into one data set. NDRs were identified as
regions of sequencing enrichment (peaks) using the software F-Seq36. We applied a feature
length of L =600 bp and a s.d. threshold of T =8.0 over the mean across a local background.
In order to reduce false-positive peak calls, we removed regions of collapsed repeats as
recently described, applying a threshold of 0.1%45. For each associated locus, candidate
functional SNPs were selected by identifying all biallelic SNPs with an r2 >0.8 and within 1
Mb of the sentinel SNP in the European samples of the 1000 Genomes Project (data released
June 2011).
D. melanogaster gene-silencing models
We used haemocyte-specific RNAi silencing to investigate whether the 121 candidate genes
identified in the red blood cell GWAS influenced blood cell formation in D. melanogaster.
We identified D. melanogaster genes predicted to be orthologues of human genes using the
Ensembl v65 Compara pipeline, an established phylogenetic-tree-based approach for
orthology prediction46; this revealed 96 D. melanogaster orthologues for 74 of the 121
human candidate genes (Supplementary Table 27). We evaluated each of the 96 orthologues
for a blood cell phenotype in D. melanogaster. We obtained all 225 available D.
melanogaster lines carrying inducible siRNA constructs from the Vienna Drosophila RNAi
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Center (VDRC)23. To achieve haemocyte-specific knockdowns, flies were crossed to the
blood-specific Hml-Gal4 line driving Gal4 expression under the control of a hemolectin
promoter47. Flies were crossed at 29 °C, and early and late L3 larvae analysed 7 days after
mating. Upstream activating sequence–green fluorescent protein enabled microscopic
visualization of plasmatocytes and evaluation of cell size and cell number (L3 larvae only).
Early- and late-stage larvae were incubated at 60 °C for 15 min, a process that turns the
crystal cells black and allows quantification of crystal cells microscopically. For each
orthologue, all available RNAi silencer constructs were investigated, and in addition, each
construct was assayed in duplicate, blind to initial result. Cell counts were quantified
visually (0–3, decreased or increased) and the mean of the duplicate measurements
calculated.
We separately carried out permutation testing in a genome-wide screen of 5,658 D.
melanogaster genes to simulate expectations under the null hypothesis (Supplementary Fig.
8 and Supplementary Note); results confirmed that the 121 candidate genes were enriched
for blood cell phenotype in D. melanogaster orthologues (P <0.05), and showed that this was
robust to threshold for calling.
Contribution of the genetic loci identified to population variation in red blood cell
phenotypes
This was investigated in participants from the Estonian Genome Center of University of
Tartu (EGCUT), LIFELINES, Ludwigshafen Risk and Cardiovascular Health Study
(LURIC) and Young Finns cohorts using samples that were not included in the discovery
experiment (Supplementary Table 1). The contribution of the SNPs to population variation
in red blood cell phenotypes was quantified using two models: model 1, limited to SNPs
associated with respective phenotype at P <1 × 10−8; and model 2, comprising all of the 75
sentinel SNPs identified. Estimates of population variance explained were made in each
study separately, and average values calculated weighted by sample size (Supplementary
Table 21).
We then investigated whether the 75 sentinel SNPs influenced the probability of being in the
highest versus the lowest quartile for population distribution of phenotype. Two SNP scores
were calculated for each phenotype: score 1, limited to SNPs associated with respective
phenotype at P <1 × 10−8, and score 2, containing all 75 sentinel SNPs identified. For both,
SNP score was calculated as the sum of number of effect (trait raising) alleles present,
weighted according to effect size. We then calculated the odds ratio for being in the highest
versus the lowest quartile of phenotype, associated with SNP scores in the second, third and
fourth quartiles, compared to first quartile of SNP score. Odds ratios were calculated in each
study separately, and then combined by inverse variance meta-analysis (Fig. 3).
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Figure 1. Gene-expression patterns for 121 putative candidate genes, and tissue distribution of
NDRs
a, Heat-map of candidate genes in the Differentiation Map of Hematology13. Cell acronyms
refer to original source (summarized in Supplementary Table 15). Expression above a log2
signal intensity (SI) of 6 is consistently above background. b, −log10 P of the signed-rank
test for candidate genes being more highly expressed in each cell type than non-candidate
genes. c, Time-course of differentiation of cord-blood haematopoietic stem cells cultured
along the erythroid lineage. Putative candidate genes are shown as upregulated (red),
downregulated (blue) or with the slope not being significantly different from zero (grey). d,
Tissue distribution of NDRs containing a potential causal variant. NDRs were ranked by
peak score (proportional to their peak height in FAIRE-seq). The rankings were then used to
divide the NDRs into cumulative tranches to explore the effect of calling-thresholds on
results (left bar, tranche containing the 5,000 top-ranked NDRs of each cell type;
penultimate bar, tranche containing the 50,000 top-ranked NDRs of each cell type). The
solid line indicates the number of SNPs overlapping the tranche-specific NDRs that are
potential causal variants (defined as a sentinel SNP from the red blood cell GWAS, or a SNP
in high linkage disequilibrium (r2 >0.8) and located within 1 Mb of a sentinel SNP; right-
hand y axis); the bar summarizes the tissue distribution of these SNPs (as a percentage of
tranche-specific total). The right-hand bar represents the expected tissue distribution for the
SNPs under the null hypothesis. Results show that the potential causal variants are most
commonly found in erythroblast-specific NDRs, and that this is true across the spectrum of
peak-calling thresholds.
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Figure 2. RNAi silencing in D. melanogaster
a, Plasmatocytes imaged by green fluorescent protein expression (light green spots on
posterior dorsal end of L3 larvae) from wild-type (WT) cells and cells with RNAi silencing
of orthologues of the following human genes: CRHR1 (106381, increased cell counts (CC)),
KIT (13502, decreased CC) and CCNA2 (32421, increased CC). Numbers represent the
unique Flybase IDs corresponding to the D. melanogaster orthologues. Scale bar, 0.5 mm.
Bottom right, plasmatocyte size is also increased in CCNA2 compared to wild type. Scale
bars, 0.1 mm. b, Crystal cells (black spots visualized by heating larvae to 60 °C) in wild-
type larvae, and in RNAi silencing of ATP5O (12794, increased CC), UBE2L3 (110767,
decreased CC) or ATP2B4 (101743, aggregated). Scale bars, 0.5 mm.
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Figure 3. Association of SNP score with red blood cell phenotypes
Results presented as odds ratio (95% confidence interval) for participants in each SNP score
quartile (Q) having phenotype level in the top quartile versus the lowest quartile of the
respective population distribution, compared to people in the lowest quartile of SNP score
(Q1, reference group). HB, haemoglobin; n, number of participants in the respective
comparison of SNP score quartiles.
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